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Abstract
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative
Staphylococcus (MRCoNS) are among the main causes of nosocomial infections, which have caused major
problems in recent years due to continuously increasing spread of various antibiotic resistance features. Apparently,
vancomycin is still an effective antibiotic for treatment of infections caused by these bacteria but in recent years,
additional resistance phenotypes have led to the accelerated introduction of newer agents such as linezolid,
tigecycline, daptomycin, and quinupristin/dalfopristin (Q/D). Due to limited data availability on the global rate of
resistance to these antibiotics, in the present study, the resistance rates of S. aureus, Methicillin-resistant S. aureus
(MRSA), and CoNS to these antibiotics were collected.
Method: Several databases including web of science, EMBASE, and Medline (via PubMed), were searched
(September 2018) to identify those studies that address MRSA, and CONS resistance to linezolid, tigecycline,
daptomycin, and Q/D around the world.
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Result: Most studies that reported resistant staphylococci were from the United States, Canada, and the European
continent, while African and Asian countries reported the least resistance to these antibiotics. Our results showed
that linezolid had the best inhibitory effect on S. aureus. Although resistances to this antibiotic have been reported
from different countries, however, due to the high volume of the samples and the low number of resistance, in
terms of statistical analyzes, the resistance to this antibiotic is zero. Moreover, linezolid, daptomycin and tigecycline
effectively (99.9%) inhibit MRSA. Studies have shown that CoNS with 0.3% show the lowest resistance to linezolid
and daptomycin, while analyzes introduced tigecycline with 1.6% resistance as the least effective antibiotic for
these bacteria. Finally, MRSA and CoNS had a greater resistance to Q/D with 0.7 and 0.6%, respectively and due to
its significant side effects and drug-drug interactions; it appears that its use is subject to limitations.
Conclusion: The present study shows that resistance to new agents is low in staphylococci and these antibiotics
can still be used for treatment of staphylococcal infections in the world.
Keywords: Linezolid, Daptomycin, Tigecycline, Quinupristin/Dalfopristin, Synercid, Meta-analysis, S. aureus, MRSA,
CoNS
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) and
methicillin-resistant coagulase-negative staphylococci
(MRCoNS) represent main causes of hospital- and
community-acquired infections; because of their increas-
ing numbers and elevated mortality, morbidity, and
medical expenses, they have become a global concern in
recent years [1, 2]. Staphylococci contain virulence fac-
tors and toxins that cause various diseases including
blood, skin and soft tissues infections, nosocomial infec-
tions connected with the presence of medical devices,
and toxic shock syndrome [3]. The mecA gene, located
in the SCCmec region, is responsible for the expression
of methicillin resistance through PBP2a—an altered
penicillin-binding protein that is characterized by its low
affinity to penicillin and other beta-lactam drugs [4]. For
both MRSA and MRCoNS vancomycin is used as the
first line drug for treatment. However, in recent years,
decreased susceptibility and even resistance to vanco-
mycin and other antibiotics, including aminoglycosides,
tetracyclines, and lincosamides, have been reported in
many parts of the world [5–7]. Therefore, for the treat-
ment of severe infections caused by multi-drug resistant
staphylococci, new antibiotics such as daptomycin, linez-
olid, tigecycline, and Quinupristin/Dalfopristin (Q/D)
were introduced [8]. Daptomycin, a cyclic lipopeptide
antibiotic, is the second most important anti-MRSA
drug, which received FDA approval in 2003 and approval
by the European Medicines Agency (EMA) in 2005. It is
mostly used for the treatment of acute bacterial skin and
soft tissues infections [9]. Daptomycin is still quite active
against staphylococci and enterococci; however, resist-
ance to this antibiotic has been reported over the past
years due to mutation of various genes (dltABCD genes,
mprF and rpoB), causing changes in membrane fluidity,
cell wall thickness, and membrane charge [10, 11]. Tige-
cycline is an example of a new class of broad-spectrum
antimicrobial agents known as glycylcyclines with activity
against Gram-positive and Gram-negative organisms. This
antibiotic was approved by FDA (2005–2009) for the
treatment of skin infections, intra-abdominal infections
and community-acquired bacterial pneumonia [12, 13].
Tigecycline provides an alternative treatment for compli-
cated MRSA and vancomycin resistant enterococci (VRE)
infections; due to mutations in mepR and mepA genes
that result in overexpression of efflux pumps, resistant
phenotypes have been reported in recent studies [13]. Li-
nezolid is another new antibiotic that was approved in
2000 for the treatment of MRSA and MRCoNS infections
and infections caused by VRE. Linezolid binds to the 50S
ribosomal subunit of the 23S rRNA molecule and inhibits
protein synthesis. Cfr gene encodes a methyltransferase
that modifies the 23S rRNA site of the 50S ribosomal sub-
unit and prevents linezolid from binding to it [14]. Q/D is
composed of two streptogramins (70% dalfopristin (strep-
togramin A) and 30% quinupristin (streptogramin B)),
which was approved in 1999 as a treatment option for
VRE and MRSA infections. This drug consists of quinu-
pristin that inhibits late-stage protein synthesis, while dal-
fopristin inhibits early-stage protein synthesis. It should be
noted that, Synercid® (formerly RP59000; Rhone-Poulenc)
is the first semisynthetic injectable streptogramin and it is
used as a trade name for Q/D [15, 16]. The World Health
Organization (WHO) has considered MRSA as important
antibiotic-resistant bacteria and put them on their priority
list. All organisms on that list require new treatment mo-
dalities and substantiate an urgent overall need for new
antimicrobial drugs [17]. According to the authors’ know-
ledge, no comprehensive data are available on the resist-
ance levels to daptomycin, Q/D, linezolid, and tigecycline
among MRSA and MRCoNS strains. This study aims to
investigate the prevalence of resistance to the mentioned
antibiotics among staphylococcal strains isolated from
clinical samples around the world.
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Methods
We conducted a literature search through databases, in-
cluding web of science, EMBASE, and Medline (via
PubMed), using the versions of September 2018. The
historic publication year was unrestricted and the search
was limited to original articles. The following search
keywords were obtained from the National Library of
Medicine’s medical subject heading (MeSH) terms or ti-
tles or abstracts with the help of Boolean operators (and,
or): “staph”, “staphylococcus”, “staphylococci”, “staphylo-
coccal”, “staphylococcaceae” and “Linezolid”, “Daptomy-
cin”, “Tigecycline”, “Quinupristin/Dalfopristin”, and
“Synercid”. Two independent reviewers screened the ti-
tles and abstracts of original articles and posters; if an
article appeared relevant (Figs. 1 and 2), the full text was
reviewed. We used the Clinical and Laboratory Stan-
dards Institute (CLSI) and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) for dap-
tomycin, linezolid, Q/D resistance and tigecycline resist-
ance in Staphylococci, respectively (there is no standard
for tigecycline in staphylococci in the CLSI). The resist-
ance cut-off rates are defined in the following ranges ≤1
mg/L, ≥8 mg/L, ≥4 mg/L, and > 5mg/L, respectively. We
considered all articles that evaluated antibiotic resistance
by different methods such as broth microdilution
(BMD), agar dilution, disk diffusion (DD), E-test and
Vitek or Vitek 2 or any other automated instruments. It
should be noted that, the final version of the CLSI
(2018) states that staphylococci with resistant results to
linezolid by DD should be confirmed by using an MIC
method, therefore, studies that only used the DD
method for susceptibility to the linezolid were excluded.
Moreover, case reports, basic research on the resistance
mechanism of the mentioned antibiotics, and review ar-
ticles were excluded from this study.
Meta-analysis
Quality assessment
All reviewed studies were subjected to a quality assess-
ment (designed by the Joanna Briggs Institute) and only
Fig. 1 Flow chart detailing review process and study selection for linezolid and daptomycin
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high-quality investigations were evaluated in our final
analysis [18–116].
Data analysis
The analysis was performed by STATA (version 14.0)
software. The data were pooled using a fixed effects
model (FEM) [117] and a random effects model (REM)
[118]. Statistical heterogeneity was assessed by statistical
methods [119] and was evaluated using the Q-test and
the I2 statistical methods [118]. P-value < 0.1 was
regarded as statistically significant [120].
Results
This study identified 1813, 2222, 512, and 636 articles for
daptomycin, linezolid, Q/D (Synercid), and tigecycline, re-
spectively, in the first step. Then, upon secondary screen-
ing, a large number of articles were excluded on the basis
of title and abstract evaluation because of the lack of rele-
vance to the study principles, and the reasons for the dele-
tion of these articles are presented in Figs. 1 and 2.
Therefore, 477, 768, 124, and 214 articles for the men-
tioned antibiotics were reviewed with full text, and a num-
ber of papers were excluded from the study for the
reasons listed in Figs. 1 and 2. Finally, 37, 51, 17, and 22 eli-
gible studies for daptomycin, linezolid, Q/D, and tigecycline
were chosen for final analysis, respectively. Resistance per-
centage in S. aureus, MRSA and CONS to the mentioned
antibiotics is shown in Table 1. The characteristics of the in-
cluded articles are summarized in Tables 2, 3, 4 and 5. All
pertinent studies were included from around the world (25
different countries) (Tables 2, 3, 4 and 5). The USA was the
most frequently represented country for all antibiotics
followed by Canada and European countries (Italy and
Spain). From the African continent, only one study from
Nigeria, where tigecycline resistance in one isolate was re-
ported (Fig. 3). Linezolid-resistant staphylococci from 15
countries were included in the present study, which was
more widely distributed among antibiotics (Fig. 4). Strains
were isolated from various clinical samples including blood,
wound, skin, urine, respiratory tract, sputum, catheter, bone,
Fig. 2 Flow chart detailing review process and study selection for Q/D and tigecycline
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etc. A majority of studies used BMD, E-test, agar dilution,
disk diffusion, and Vitek or vitek 2. Our results showed that
linezolid had the best inhibitory effect on S. aureus. Although
resistance to the linezolid has been reported from different
countries, due to the high volume of the samples and the
low number of resistance, in terms of statistical analyzes, the
resistance to this antibiotic is zero. Moreover, linezolid and
tigecycline effectively (99.9%) inhibit MRSA (Table 1). Stud-
ies have shown that CoNS with 0.3% show the lowest resist-
ance to linezolid and daptomycin, while analyzes introduced
tigecycline with 1.6% resistance as the least effective anti-
biotic for these bacteria. Finally, MRSA and CoNS had a
greater resistance to Q/D with 0.7 and 0.6%, respectively.
Discussion
MRSA is a frequent cause of skin and soft tissue infec-
tion, pneumonia, endocarditis, bone and joint infection
in individuals with some risk factors such as indwelling
devices, surgical interventions, long-term antibiotic use,
intensive care admission, and dialysis [121, 122]. In re-
cent years, this bacterium has had very high health costs
for patients due to increased length of hospital stay and
longer duration of antibiotic treatment [123]. Moreover,
CoNS are opportunistic pathogens that lead to 30% of
hospital-induced infections and 10% of uncomplicated
urinary tract infections in young women and native valve
endocarditis, especially in immunocompromised patients
[124, 125]. Currently, the treatment of MRSA and CoNS
is difficult due to the high antibiotic resistance to beta-
lactams and other antibiotic classes, and newer agents
such as linezolid, daptomycin, Q/D, and tigecycline can
be used as alternative if available and deemed cost-
effective. Accordingly, this study collected data from re-
sistance to these antibiotics all over the world to deter-
mine the extent of their clinical application. The analysis
of the results showed that linezolid had the highest inhibi-
tory effect on S. aureus; due to the high volume of the
samples in the studies and a small number of bacteria that
have been reported as resistant (mostly in the United
States), in terms of statistical analyses, the percentage of
resistance to this antibiotic is zero (Table 1). It should be
noted that the studies (20 studies) that used the DD
method as an antibiotic susceptibility test for linezolid
were removed from this study and not entered into statis-
tical analyses. Furthermore, the most linezolid-resistance
S. aureus isolates isolated from pneumonia and blood in-
fections were the highest in number. In addition to the
good effect of linezolid on S. aureus, this drug also had
the efficient activity against MRSA, while the resistance of
CoNS was higher to this antibiotic. One of the reasons for
the increased resistance in CoNS is the ability of these
bacteria to develop resistance quite easily following linezo-
lid exposure, even though this has not been proven
in vitro, to the best of our knowledge. Furthermore, more
Linezolid-resistant CoNS (LRCoNS) were associated with
outbreaks; 50% of those studies that analysed LRCoNS in-
volved clonal LRCoNS across one or more patients and fa-
cilities. The studies that used MLST for typing of
resistant-linezolid CoNS, ST5, ST22 and for S. aureus
ST228, ST8 and ST5 were reported to be more sequence
types related to linezolid resistance [25, 67].
Tigecycline had the best effect (equal to linezolid)
on MRSA, and very low resistance in S. aureus was
observed; however, CoNS with 1.6% showed the high-
est percentage of resistance to this antibiotic (Table
1). Since very few studies have reported the resistance
of CoNS to tigecycline (Fig. 3), the high percentage of
resistance noted by tigecycline cannot be deemed.
The geographic diversity of the countries that re-
ported the tigecycline resistance was higher than
those with linezolid, thus showing more use of this
antibiotic in different parts of the world. Recent
MRSA infection treatment guidelines have not incor-
porated tigecycline. The reason is the FDA’s Septem-
ber 2010 safety statement, which describes increased
overall mortality among severely infected patients
Table 1 Resistance percentages in S. aureus, MRSA and CoNS to different antibiotics
S. aureus
Linezolid Daptomycin Tigecycline Q/D
Resistance rate (%) 0.0%[CI% (0.0–0.0)] 0.1 [CI% (0.1–0.1)] 0.1 [CI% (0–0.1)] 0.1 [CI% (0.1–0.2)]
p-value 0.04 0.02 0.09 0.88
MRSA
Resistance rate (%) 0.1 [CI% (0–0.1)] 0.1 [CI% (0.1–0.1)] 0.1 [CI% (0–0.1)] 0.7 [CI% (0.3–1)]
p-value 0.33 0.00 0.00 0.00
CoNS
Resistance rate (%) 0.3 [CI% (0.2–0.4)] 0.3 [CI% (0.2–0.4)] 1.6 [CI% (1.2–1.9)] 0.6 [CI% (0.3–0.9)]
p-value 0.04 0.37 0.00 0.00
MRSA; Methicillin-resistant Staphylococcus aureus, CoNS; Coagulase-negative staphylococci, Q/D; Quinupristin / Dalfopristin
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Table 3 Characteristics of the articles that were included in the meta-analysis and reported resistance to Q/D





































Picazo [85] 2010 2011 Spain 702 503 187 199 1 1 3 BMD Medical
canters
Sader [103] 2002–2004 2006 Germany 1232 715 517 1 1 BMD Skin
infection,
Blood
Sader [103] 2002–2004 2006 Italy 685 386 299 1 BMD Skin
infection,
Blood
Sader [103] 2002–2004 2006 UK 593 531 62 1 BMD Skin
infection,
Blood
Draghi [36] 2004 2005 USA 3368 2872 1556 496 2 BMD Skin, Blood,
Respiratory
tract
Ballow [21] 2002 North
America




2000 2003 France 364 242 87 122 1 1 E-test Blood




2003 Turkey 149 149 52 30 5 BMD Clinical
specimens










360 360 360 6 6 BMD Hospital
Picazo [82] 2008 2009 Spain 703 520 201 183 5 5 BMD Blood
Jones [63] 2007 2008 USA 4338 3318 1930 1020 2 2 BMD Medical
canters
Pfaller [80] 2002–2005 2010 USA 13,053 10,
917
4947 2136 1 BMD Medical
canters
John [58] 2002 Canada 658 658 15 Agar dilution Patient in
hospitals
Sader [103] 2002–2004 2006 France 1479 1100 379 16 7 BMD Skin
infection,
Blood
Sader [103] 2002–2004 2006 Greece 185 128 57 2 BMD Skin
infection,
Blood
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who are treated with tigecycline; besides, cause of the
excess deaths in these trials usually remains uncertain.
However, it is likely that most cases of death among
such patients were associated with the infection pro-
gression. Moreover, this antibiotic is not authorized
for pneumonia or diabetic foot infections. Although
tigecycline is recommended for treating skin and soft
tissue infections, previous studies have shown no sig-
nificant difference between this antibiotic and other
new drugs, and tigecycline is referred to as the sec-
ond or third line of treatment for infections caused
by MRSA [126, 127]. Therefore, although the present
study showed that S. aureus resistance to tigecycline
is low, the use of this drug still has limitations in
treating staphylococcal infections. Daptomycin is an-
other new drug used to treat infections caused by
Gram-positive bacteria including MRSA and VRE. It
kills microorganisms by rapid membrane depolymer-
isation, loss of membrane potential and disruption of
DNA, as well as RNA and protein-synthesis [128].
The daptomycin resistance among staphylococcal
strains has been reported from around the world, al-
though there has been no resistance report from the
African continent. The United States had the highest
rate of resistance (42.5% of studies); India, Taiwan,
and Saudi Arabia reported resistance to this antibiotic
from the Asian continent, and most of the bacteria
were isolated from wounds and blood infections. In
the United States and Europe, daptomycin is used for
treating skin and soft tissue infections, bacteraemia,
and endocarditis caused by S. aureus [129]. Previous
studies have reported that it is not very practical to
use daptomycin for the treatment of pneumonia, be-
cause it is deactivated by pulmonary surfactants.
Therefore, vancomycin and linezolid are recom-
mended to treat pneumonia caused by MRSA [130].
Our results have shown that daptomycin has the best
performance with linezolid regarding CoNS, indicating
that this antibiotic can be used for a therapeutic ap-
proach to infections caused by these bacteria.
Furthermore, the present study showed that resistance
to daptomycin has been very low (0.1–0.3%); consid-
ering that this antibiotic shortens the duration of the
treatment of soft-tissue infections due to MRSA com-
pared to vancomycin [131], it can be used to a
greater degree for treating the mentioned infections.
However, spontaneous resistance to daptomycin
seems to occur rarely [132], and vancomycin can also
decrease the function of this drug [130, 133]. There-
fore, it is possible to isolate daptomycin-resistant
strains from the areas where this antibiotic is not
even used, and physicians usually use alternative
agents (linezolid and vancomycin) instead of dapto-
mycin, which can be considered as a factor. Daptomy-
cin can be one of the choices for treating
staphylococci-induced infections if there is a strong
possibility based on local microbiological data or re-
cent treatment history of vancomycin in an infected
patient with MIC of > 1 μg/mL.
Q/D comprises quinupristin and dalfopristin in a
30:70 ratio, which prevents protein synthesis in bac-
teria [134]. Studies have shown that Q/D with 0.7%
has the highest resistance rate amongst MRSA strains
(Table 1). Resistance reports were gathered from the
continents of America, Asia, and Europe, although
more studies have been carried out in European
countries. This antibiotic is used for the treatment of
VRE bloodstream infection and complicated skin and
soft tissues infections caused by MRSA and Strepto-
coccus pyogenes. However, the results of this study
showed that Q/D had a weaker inhibitory effect than
linezolid and daptomycin on S. aureus, MRSA, and
CoNS (Table 1); on the other hand, it has significant
side effects (myalgia, arthralgia, increased alkaline
phosphatase, and nausea), high drug interactions, and
treatment costs [135], which led to the limited use of
this antibiotic. Therefore, it is better to use other new
alternative antibiotics instead of Q/D for treating of
staphylococcal infections. The present study showed
that although linezolid, Q/D, daptomycin, and
Table 3 Characteristics of the articles that were included in the meta-analysis and reported resistance to Q/D (Continued)
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Abbreviations: DD; disk diffusion, BMD; broth microdilution
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tigecycline are prescribed by clinicians for about 15
to 20 years, there is still very low resistance to these
antibiotics around the world. On the other hand, with
the increasing resistance of staphylococci to vanco-
mycin and the high side effects of other drugs such
as cotrimoxazole, it seems that these antibiotics have
to be used more often in the future. The results of a
recent study on the global prevalence of vancomycin-
nonsusceptible MRSA showed that the prevalence of
vancomycin-intermediate S. aureus (VISA) was 3.01%
in 68,792 MRSA strains. Furthermore, the pooled
prevalence of heterogeneous vancomycin-intermediate
S. aureus (hVISA) was 6.05% and is highly dangerous,
because these bacteria lead to higher rates of vanco-
mycin treatment failure. It should be noted that this
study reported that the rate of vancomycin-
nonsusceptible MRSA has been increasing in recent
years, and this is a danger to the international com-
munity [136]. It should be noted that, still, some dis-
eases caused by Staphylococcus genus, such as
pneumonia, are treated easier with older drugs, and
more studies are needed to evaluate the effect of the
newer agents. The higher rates of resistance to the men-
tioned antibiotics in the United States and European
countries compared to other parts of the world do not
imply higher resistance to these antibiotics in this areas
and are related to microbial susceptibility testing pro-
grams that are regularly carried out in these countries,
while there are no such reports in the African and Asian
countries (may because of non-availability and elevated
prices in these regions). Therefore, by performing such
programs in other countries, the exact resistance rates of
the staphylococcal strains to the newer Gram-positive
cocci antibiotics can be determined.
Fig. 3 The global prevalence of a) Tigecycline, b) Quinupristin/Dalfopristin-resistant S. aureus, MRSA and CoNS
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Conclusion
The present study shows that resistance to new agents is
low in staphylococci and these antibiotics can still be
used for treatment of staphylococcal infections in the
world. It should be noted that the development of resist-
ance to these antibiotics should be prevented by appro-
priate antibiotic resistance testing programs.
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